טוען...

Clinical and virological outcomes of TB/HIV co-infected patients treated with dolutegravir-based HIV antiretroviral regimens: Programmatic experience from Botswana

BACKGROUND: Dolutegravir (DTG) has recently been recommended as a preferred first-line regimen for the treatment of new and treatment experienced HIV infected patients. However, potential drug interactions between DTG and rifampicin remain a clinical and public health concern. METHODS: We analyzed H...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
הוצא לאור ב:	J Acquir Immune Defic Syndr
Main Authors:	Modongo, Chawangwa, Wang, Qiao, Dima, Mbatshi, Matsiri, Ogopotse, Kgwaadira, Botshelo, Rankgoane-Pono, Goabaone, Shin, Sanghyuk S, Zetola, Nicola M
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	2019
נושאים:	Article
גישה מקוונת:	https://ncbi.nlm.nih.gov/pmc/articles/PMC7794061/ https://ncbi.nlm.nih.gov/pubmed/31335593 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000002126
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

Clinical and virological outcomes of TB/HIV co-infected patients treated with dolutegravir-based HIV antiretroviral regimens: Programmatic experience from Botswana

פריטים דומים